Nymox Reports Positive Safety Monitoring Committee Results for Pivotal Phase 3 Trials
HASBROUCK HEIGHTS, N.J., Sept. 12, 2012 (GLOBE NEWSWIRE) --
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable
results from the most recent Safety Monitoring Committee review of
ongoing safety data for the Company's Phase 3 pivotal trials for
NX-1207, Nymox's investigational drug for benign prostatic
hyperplasia (BPH).
The September 4, 2012 Safety Monitoring Committee meeting found no
significant safety concerns to date. The two Phase 3 trials,
NX02-0017 and NX02-0018, are continuing with patient recruitment
and trial activities nearing completion at over 70 well-known
urology investigative sites across the U.S.
Previous clinical trials found that a single administration of
NX-1207
2.5 mg produced on average improvements in the standardized BPH
symptom score (8-10 points at 90 days) that were approximately
double that reported for currently approved BPH drugs (3-5 points)
without the sexual, blood pressure, or other side effects
associated with the approved drugs. Follow-up studies have shown
durable clinically significant benefit for up to 7 1/2 years after
a single treatment.
NX-1207 is administered in an office setting by a urologist. The
procedure does not require anesthesia, sedation or catheterization
and involves little or no pain or discomfort.
BPH is one of the most commonly diagnosed diseases in older men. The condition can have a significant negative impact on a man's health and quality of life and can lead to acute urinary retention, incontinence and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.
More information about Nymox is available at www.nymox.com,
email:
info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Posted: September 2012
